actinium ac 225 sstr2-targeted agent ryz401
Generic: Actinium Ac 225 SSTR2-targeted Agent RYZ401
actinium ac 225 sstr2-targeted agent ryz401: 1 clinical trial tracked.
actinium ac 225 sstr2-targeted agent ryz401 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about actinium ac 225 sstr2-targeted agent ryz401, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.
Primary endpoint: Dose Escalation
Interventionalopen104 targetStarted 2025-12Completion 2033-049 sites · Canada, United StatesRayzeBio, Inc.